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Introduction
Epidermal growth factor receptors (EGFRs) are 
expressed on the surface of the mammalian cells and 
play crucial roles in cell division, migration, survival, 
differentiation and development in the embryonic and 
adult tissues. Uncontrolled signalling of these receptors 
accounts for various cancers. This family belongs 
to subclass 1 of receptor kinase super family and 
have four members: HER1 (ErbB1 or EGFR), HER2 
(ErbB2), HER3 (ErbB3) and HER4 (ErbB4) (Hynes 
and Lane, 2005; Zahnow, 2006). The ErbB receptors 
have a general structure in common that includes: an 
extracellular ligand-binding domain, a transmembrane 
single helix region, and an intracellular kinase domain 
(Needham et al., 2016).
Pioneering studies have shown that these receptors 
are relevant to at least eleven EGF-related peptide growth 
factors and they have been divided into three groups. 
The first group binds only to HER1 and includes EGF, 
TGF-α, and amphiregulin (AR). The second group binds 
to HER1 and HER4 and includes betacellulin (BTC), 
heparin-binding EGF (HB-EGF), and epiregulin (EPR). 
The third group includes Neuregulin-1 (NRG-1) and 
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NRG-2 that bind to both HER3 and HER4 and NRG-3 and 
NRG-4 that bind only to HER4 (Zahnow, 2006).
Extracellular domains (ECD) in all receptor tyrosine 
kinases (RTKs) consist of 4 regions or subdomains named 
DI, DII, DIII and DIV. DI and DIII are leucine-reach and 
responsible for ligand attachment. DII and DIV with high 
levels of cysteine residues, are responsible for di-sulfide 
bond formation and receptor consistency (Olayioye et al., 
2000; Cho and Leahy, 2002).
Ligand binding to ECD serves as an activation 
factor and induces homo- or heterodimer formation and 
following kinase domain activation, it phosphorylates 
specific tyrosine residues. These phosphorylated 
residues recruit some adaptor proteins which can activate 
downstream signalling (Olayioye et al., 2000).  
Contrary to the other HER receptors, HER3 has an 
inactive kinase domain. In the human, chromosome 
12q13 encodes the HER3 genes which is translated to 
a 185 kDa glycoprotein (Kraus et al., 1989; SIERKE et 
al., 1997). This receptor can be overexpressed in some 
cancers and studies have proven the importance of HER3 
in malignancies such as melanoma, breast, lung, prostate, 
ovarian and colorectal cancers (Amin et al., 2010; Ma et 
al., 2014; Zhang et al., 2015). 
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Due to the inactive kinase domain, homo-dimer 
formation in HER3 receptor cannot induce an active 
downstream signal, so it is the best partner for heterodimer 
complex formation. This receptor has also been shown 
to preferentially pair with HER1 and HER2 and is 
overexpressed in cancers along with HER1 and HER2. 
Furthermore, since HER2 has no known ligand and is 
always in an open conformation, HER3 is considered 
as a necessary dimerization partner for HER2 and is 
the strongest one among all heterodimers (Holbro et al., 
2003; Schulze et al., 2005; Jones et al., 2006; Ma et al., 
2014; Miller et al., 2014). Dimerization of HER3 with 
HER2 may lead to HER2 targeted treatment failure and 
multi-drug resistance in cancers (Schulze et al., 2005; 
Ma et al., 2014).
Considering HER molecular structures and their 
importance in tumor pathogenesis, different modalities 
of targeted therapies have been developed. Several 
monoclonal antibodies have so far been produced against 
HER3. These monoclonal antibodies are in different 
phases of clinical trial but none of them have been able 
to acquire FDA approval, yet (Jiang et al., 2012; Gaborit 
et al., 2015). Parallel attempts to develop appropriate 
immunotherapeutic approaches for induction of active 
immune responses are noticeable but few studies have 
been devoted to HER3.
The main objective of this study was to evaluate the 
antibody response to different subdomains of HER3 
extracellular domain (HER3-ECD) and the anti-tumor 
activity of these antibodies on HER3 expressing tumor 
cells. To this end, we produced recombinant paired 
subdomains of DI+II and DIII+IV as well as full 
HER3-ECD proteins in CHO host cells. Subsequently, 
rabbits were immunized with recombinant proteins 
and then purified polyclonal antibodies were used for 
assessment of their inhibitory effects on HER2/HER3 
expressing tumor cell lines (BT-474 and JIM-T1).
Materials and Methods
Production of expression constructs
Extracellular domain and subdomain genes of human 
HER3-ECD were amplified using specific primers (Table 
1) and a vector containing full length of HER3 coding 
sequence as a template (kindly provided by Professor 
Bridget S. Wilson) (Steinkamp et al., 2014). For the 
purpose of detection and purification, the domains were 
fused to mouse IgG2a region gene. The PCR products were 
subcloned into pSecTag2/hygro eukaryotic expression 
vector (OriGene, Maryland, USA) which had already 
contained the sequence of mouse IgG2a Fc fragment 
(prepared in our lab) using SmaI and BstBI restriction 
enzymes. All final constructs were verified by automated 
sequencing before they were applied for transfection.
Transfection, expression and purification of the fusion 
proteins 
We cultured CHO-K1 cells (National Cell Bank of Iran, 
Pasteur Institute, Iran) were cultured in RPMI-1640 medium 
(Gibco, California, USA) supplemented with 10% heat 
inactivated fetal bovine serum (Gibco, California, USA), 
1% penicillin (100 IU/ml) and streptomycin (100 μg/mL) 
(Gibco, California, USA) and used lipofectamine 2000 
(Invitrogen, California, USA) in a protocol recommended 
by the manufacturer to transiently transfect CHO-K1 
cells. We seeded 2.5×105 CHO-K1 cells in every well of 
12-well plates. Next day, after washing the cells with pure 
RPMI or sterile 1X PBS, 300 µl of Opti-MEM medium 
(Invitrogen) was added to every well. Four µg of each 
construct were diluted in 100 µl Opti-MEM (Invitrogen) 
and besides, 3 µl lipofectamine 2000 were added to 100 
µl Opti-MEM. Opti-MEM medium containing DNA was 
added to the mixture of Opti-MEM and lipofectamine 
2000. After 5-20 minutes incubation at room temperature, 
the lipid-DNA mixture was added to each well. Then, the 
cells were incubated at 37°C in 95% air and 5% CO2. The 
day after transfection, 500 µl Opti-MEM medium were 
added to each well and finally, 48 hour after transfection, 
cell supernatants were transferred into clean microtubes. 
Protein concentration of each sample was measured by 
a non-specific ELISA. Next, for choosing the stably 
expressing clones, cells were grown in 0.7 mg/ml 
Hygromycin for 10-12 days and subcloned four times. In 
the end, stable clones were cultured in serum free medium 
at a large scale and their supernatants were collected for 
protein purification. Because of the presence of mouse Fc 
in the structure of HER3-Full ECD and its subdomains, 
we used HiTrap protein G HP column (GE Healthcare, 
Buckingham, UK) for purification of the expressed fusion 
proteins.
Screening of protein expression by ELISA
A non-specific sandwich ELISA using rabbit anti 
mouse Ig and HRP-conjugated rabbit anti mouse Ig 
(SinaBiotech Co., Tehran, Iran) was developed to detect 
the fusion proteins. Briefly, 50 µl of 5 µg/ml of rabbit 
anti mouse Ig, dissolved in PBS, were coated in a 96-well 
flat bottom microtiter plate (Maxisorp, Nunc, Roskilde, 
Denmark) and the plate was incubated at 37°C for 90 
minutes. Then, the plate was washed with PBS-Tween 20 
(0.05% Tween 20) for three times. Nonspecific binding 
sites were blocked for 90 minutes at 37°C with PBS-Tween 
20 (0.05%) containing 3% skim milk (Merck, Darmstadt, 
Germany) and the plate was washed three times. Culture 
supernatants at different dilutions were added to wells 
and incubated in 37°C for 60 minutes. After three times 
washing, HRP-conjugated rabbit anti mouse Ig at suitable 
dilution was added and incubated at 37°C for another 60 
minutes. After washing, tetramethylbenzidine (TMB) 
substrate (Pishtaz Teb, Karaj, Iran) was added in each well 
and the reaction was stopped by adding 1N HCL and then 
Optical Density (OD) was measured by an ELISA reader 
(BioTek, Winooski, VT, USA) at 450 nm.
Rabbit immunization by recombinant proteins
Female New Zealand white rabbits (Razi Vaccine and 
Serum Research Institute, Karaj, Iran) were immunized 
intramuscularly with 50 µg of HER3-Full ECD domain 
and subdomains dissolved in 500 µL of 1X PBS  and 
emulsified in 500 µL of complete Frund’s adjuvant 
(Sigma, St Louis, MO, USA). The subsequent four 
booster injections with 25 μg of recombinant proteins 
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Cross-reactivity assessment of polyclonal antibodies with 
other HER family members
An indirect ELISA was designed to determine 
cross-reactivity between anti-HER3 Full ECD and 
other HER family members (HER1, HER2 and HER4). 
Briefly, commercial recombinant HER1, HER2, HER3 
and HER4 proteins (Speed BioSystems, Rockville, MD, 
USA) with 1 µg/ml concentration were coated in 96-well 
plates for 90 minutes at 37°C. HRP-anti-His tag was used 
for confirmation of the coating layer. After washing and 
blocking, anti-HER3 Full ECD and subdomains were 
added at different concentrations (10, 2.5, 0.625 µg/ml) 
to the plates and incubated at 37°C for 60 minutes. One 
hour incubation in the presence of HRP-conjugated sheep 
anti-rabbit Ig (SinaBiotech, Tehran, Iran) at 37°C was 
done and finally, the reaction was revealed by TMB and 
after stopping by HCl, the optical densities (OD) were 
measured by an ELISA reader at 450 nm.
Analysis of reactivities of polyclonal antibodies with tumor 
cells by flowcytometry 
To prove that the produced polyclonal antibodies could 
bind to the native forms of HER3 receptors on tumor cell 
surfaces, we used flowcytometry assay on 3 breast cancer 
cell lines. BT-474, JIMT-1 and HCC-1954 cells (National 
Cell Bank of Iran) were trypsinized and washed twice 
with 1X PBS. The cells were then blocked with FACS 
5% buffer (PBS 1X, 5% FBS) for 30 minutes at 4°C. 
Anti-HER3 full ECD antibody at 20 µg/ml concentration 
was added to 5×105 cells and incubated at 4°C for 60 
minutes. We considered anti-Full ECD HER2 (Hosseini-
Ghatar et al., 2017b), PE-anti-human erbB3/HER-3 
antibody (Clone 
1B4C3, Biolegend, USA) and non-immune rabbit 
IgG as positive and negative controls, respectively. Twice 
washing with PBS was done. After 45 minutes incubation 
with 5 µg/ml of FITC-conjugated sheep anti-rabbit Ig at 
4°C, cells were washed again. In the end, 20×103 cells 
were counted for each sample with a flowcytometer 
(Partec, Nuremberg, Germany) and the data was analyzed 
with FlowJo v10 software (Tree Star, Inc, Ashland, OR, 
USA). 
Assessment of anti-tumor effects of polyclonal antibodies 
on breast cancer cell lines by XTT assay
Anti-tumor effects of the produced anti-HER3 
subdomain polyclonal antibodies were assessed on BT-474 
and JIMT-1 cells. Five thousand cells/well were seeded in 
96-well flat bottom plates in 100 µl RPMI-1640 medium 
containing 20% FBS for BT-474 and 10% for JIMT-1 and 
allowed to adhere overnight at 37°C. The cells were then 
treated with 100, 25 and 5 µg/ml of anti-HER3 Full ECD 
and 100 µg/ml of anti-subdomain antibodies and incubated 
an additional 72 hour at 37°C. 
Hundred µg/ml of HER2 Full ECD polyclonal 
antibody (Hosseini-Ghatar et al., 2017b) and 100 µg/ml of 
non-immune rabbit IgG were considered as positive and 
negative controls, respectively. After 72 hour incubation, 
we added 2, 3-bis (2 methoxy-4-nitro-5-sulfophenyl)-
5-([phenylamino]-cabonyl)-2Htetrazolium (XTT) 
solution according to the instruction of the manufacturer 
in incomplete Freund’s adjuvant (Sigma) were given 
every two weeks after the primary immunization. Sera 
of the immunized rabbits were collected weekly. Titers 
of the polyclonal antibodies were assessed by ELISA. 
High-titred sera were purified by HiTrap protein G HP 
column. The animals were maintained based on Tehran 
University of Medical Sciences guideline for ethical use.
Titration of immunized rabbit sera by ELISA
Fifty microliters of 5 µg/ml of recombinant proteins 
were coated in 96-well plates and incubated for 90 minutes 
at 37°C. After three times washing with PBS-T, blocking 
was done for 90 minutes at 37°C. Then, serial dilutions of 
rabbit sera were added to the wells and incubated for 60 
minutes at 37°C. After washing, HRP-conjugated sheep 
anti-rabbit IgG was added and incubated for 60 minutes 
at 37°C. After the final wash, the reaction was developed 
by using TMB substrate and after stopping the reaction, 
the absorbance was read at 450 nm.
Purification of polyclonal antibodies
Rabbit sera were purified in a two-step procedure. First, 
total rabbit IgG was purified by a HiTrap protein G HP 
column. Second, anti-HER3-Full ECD and subdomains 
were separated from anti-mouse Fc by using a Sepharose 
4B column coupled with mouse IgG2a mAbs (prepared in 
our laboratory) (Hosseini-Ghatar et al., 2017a). 
Confirmation of anti-mouse Fc adsorption from rabbit 
polyclonal antibodies by ELISA 
To confirm adsorption of anti-mouse Fc and isolation 
of HER3 specific antibodies, an ELISA test was carried 
out. 5 µg/ml of HER3 recombinant proteins and mouse 
Fc fragments were coated separately and incubated for 
90 minutes at 37°C. After blocking with 3% skim milk, 
adsorbed polyclonal antibodies were added and incubated 
for 60 minutes at 37°C. HRP-conjugated sheep anti-rabbit 
Ig was added and incubated at 37°C for 60 minutes. The 
reaction was revealed by TMB, stopped by HCL 1N and 
read at 450 nm. 
Purity determination and structural characterization of 
recombinant proteins by SDS-PAGE and immunoblotting 
assay
Five µg of recombinant proteins were electrophoresed 
on 10% SDS–polyacrylamide gels under reducing and 
non-reducing conditions. Mouse IgG was used as a 
positive control. 
For immunoblotting, after protein electrophoresis on 
the SDS-PAGE gel, the proteins were transferred onto a 
nitrocellulose membrane (Schleicher & Schuell, Dassel, 
Germany). The membrane was blocked by PBS-Tween 
20 (0.05%) containing 5% skim milk (Merck, Germany) 
for 60 minutes at RT. Mouse Fc-adsorbed polyclonal 
antibodies in a suitable concentration were added to their 
specific antigens and incubated overnight at 4°C. After 
three times washing with PBS-Tween 20 (0.05%) the 
membrane was incubated with HRP-conjugated sheep 
anti-rabbit at RT. In the end, positive protein bands were 
developed by ECL prime kit (Amersham Pharmacia 
Biotech, Chalfont, UK). 
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(Roche Diagnostics, Mannheim, Germany). Four hours 
incubation in the presence of XTT was done and in the 
end, the microtiter plates were read by ELISA reader 
at 450 nm. Two different experiments were carried out 
in triplicates and tumor growth inhibition rates were 
estimated by the following formula:
Tumor growth inhibition (%) = (OD without 
antibody-OD with antibody) /OD without antibody × 100
Statistical analysis  
In order to compare the groups, we used parametric 
one way ANOVA (Tukey test) and P values of less than 
0.05 were taken as significant.
Results
Production of HER3-ECD domain and subdomain 
recombinant proteins
After transfection of CHO-K1 host cells with 
HER3-Full ECD and its subdomain constructs, 
HER3-Full ECD, DI+II and DIII+IV fusion proteins 
were successfully produced in these cells (Figure 1a). 
Considering the presence of mouse Fc γ2a fragment in the 
structure of the recombinant proteins, protein expression 
could be detected in cell supernatants using mouse Ig 
specific polyclonal antibodies by ELISA.
Characterization of the purified recombinant proteins 
by SDS-PAGE
After purification of recombinant proteins from 
serum-free culture supernatants by protein G column, the 
purity and structure of the purified proteins were assessed 
by SDS-PAGE. Coomassie blue staining of SDS-PAGE 
gel showed high purity of the recombinant proteins and 
because of glycosylation in the mammalian host cells 
and dimerization by IgG2a hinge, all purified proteins 
had higher molecular weights compared to their expected 
amplicon size (Figure 1b). Different HER3-Full ECD size 
bands observed in reduced and non-reduced conditions 
are probably related to monomer, polymer or degraded 
forms. According to Table 1, the amplicon size of DI+II 
and DIII+IV is almost similar with a molecular weight 
of approximately 36 Kd. Since the hinge sequence of 
mouse Fc region is present in the construct leading to 
dimerization of the expressed proteins, the final molecular 
weight of the assembled fusion proteins would be around 
206, 134 and 137 Kd for ECD-full HER3, DI+II and 
DIII+DIV, respectively, in non reducing form. Moreover, 
the molecular weight of DIII+IV was found to be higher 
than DI+II. According to the glycosylation site prediction 
(NetNGlyc 1.0 Server, http://www.cbs.dtu.dk/services/
NetNGlyc), there are 4 times higher possible glycosylation 
positions in DIII+IV compared to DI+II which could 
justify its higher molecular weight.
Production and purification of polyclonal antibodies
The purified proteins were injected to rabbits and 
serum samples were collected after each immunization. 
Reactivities of the antibodies were tested against the 
corresponding antigens at 1/800 dilution after each 
immunization. The results indicated that the high titers of 
Domain Primer Sequence Amplicon size (bp)









Table 1. List of Primers Used for Amplification of HER3-ECD and Its Subdomains
Figure 1. Characterization of Recombinant HER3 ECD Subdomains. a) Detection of recombinant proteins in culture 
supernatant of stable transfected CHO-K1 cells; b) Electrophoresis pattern of purified recombinant proteins. Purified 
proteins were resolved on 10% SDS-PAGE gel under reducing and non-reducing conditions and then stained with 
Coomassie blue. SM, size marker (kilodalton). 
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antibodies against HER3-Full ECD, DI+II and DIII+IV 
subdomains reached plateau after administration of the 
first immunization dose and slightly increased after 
subsequent booster doses (Figure 2). 
After last immunization, rabbit sera were collected 
and purified in two steps. In the first step, total rabbit IgG 
was purified by protein G column and then specific rabbit 
anti-mouse Fc antibodies were removed by a Sepharose 4B 
column coupled with mouse mAbs. The cross reactivities 
of these adsorbed anti-HER3 Full ECD and subdomain 
antibodies were assessed by ELISA. The results showed 
that total IgG from immunized rabbits reacted with mouse 
IgG Fc fragments, but after anti-mouse Fc removal, 
adsorbed polyclonal antibodies could only react with 
their specific antigens, but not with mouse Fc fragments 
[Figure 3(a and b)]. Adsorbed polyclonal antibodies 
against DI+II and DIII+IV could recognize HER3 Full 
ECD protein in the same manner as anti-HER3-ECD 
antibody [Figure 3(c)].
Immunoblotting of purified HER3 ECD domain and 
subdomain specific polyclonal antibodies
Five µg of each recombinant protein and a mouse 
Figure 2. Titration of Serum from Rabbits Immunized with 
Recombinant HER3-ECD Proteins. After administration 
of each immunization dose, serum samples from the 
immunized rabbits were collected and tested at 1/800 
dilution against the corresponding immunogens. 
Figure 3. Reactivity of Purified Anti-HER3 ECD Proteins 
before and after Adsorption. a) Polyclonal antibodies 
were adsorbed with IgG2a and the reactivity of the 
antibodies was assessed on an IgG2a mAb before and 
after adsorption; b) Adsorbed antibodies were titrated on 
the corresponding immunizing recombinant proteins, or 
c) HER3 full ECD. 
Figure 4. Immunoblotting of HER3 ECD Domain and Sub-Domains Specific Polyclonal Antibodies. After resolving 
the recombinant proteins on 10% SDS-PAGE under reducing and non-reducing conditions, the bands were transferred 
to a nitrocellulose membrane and revealed with anti-HER3 Full ECD (a) or anti-DI+II and -DIII+IV (b) polyclonal 
antibodies. 1F2 is a mouse IgG2a monoclonal antibody which is employed as a control. SM: size marker (kilodalton)
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IgG2a monoclonal antibody (1F2) (Tahmasebi et al., 
2014) were run on SDS-PAGE gel under reduced 
and non-reduced conditions and then trasferred to 
nitrocellulose membrane as described in Materials and 
Methods. The results showed that the adsorbed anti-HER3 
full ECD antibody could recognize both HER3 full ECD 
and the two other subdomains. Since anti-HER3 full 
ECD was adsorbed, negligible reactivity with mouse 
IgG2a was observed. The immunoblotting profile is very 
similar to the SDS-PAGE results with the exception of 
the ~30Kd band observed in the reduced HER3 full ECD 
lane which is absent in the corresponding WB results. 
This band most likely represents the Fc fragment which 
could not be picked up by the Fc IgG adsorbed anti-HER3 
full ECD antibody (figure 4a). We also investigated 
the reactivities of anti-DI+II and -DIII+IV with their 
specific antigens and HER3 full ECD protein. The results 
indicated that the adsorbed anti-DI+II and anti-DIII+IV 
polyclonal antibodies could recognize their coresponding 
subdomains as well as HER3 full ECD (Figure 4b). The 
WB profile obtained with these anti-subdomain antibodies 
is somehow different from the SDS-PAGE profile. This 
could be due to utilization of two different preparations 
of purified fusion proteins for these experiments. The 
preparations employed in figure 1b is the same as that used 
in figure 4a, but different from the preparations employed 
in figure 4b. The latter preparations imply that the purified 
proteins were slightly degraded after purification, leaving 
more bands in the WB results. Similar to the SDS-PAGE 
results, purified DIII+DIV had a higher molecular weight 
than DI+II protein. 
Cross-reactivity with other HER family members
Because of homology between HER family members, 
we carried out an ELISA to determine if anti-HER3 Full 
ECD could react with other HER family members. So we 
titrated polyclonal anti-HER3 Full ECD on commercial 
recombinant HER1, HER2, HER3, HER4 proteins along 
with our purified HER3 Full ECD fusion protein. The 
results indicated that the adsorbed anti-HER3 full ECD 
could recognize our purified HER3-ECD similar to the 
Figure 5. Cross Reactivity of Anti-HER3 Full ECD with 
HER Family Members. Adsorbed anti-HER3 full ECD 
antibody was tested against 2.5 µg/ml of four commercial 
recombinant HER family members as well as HER3 full 
ECD prepared in this study.
Figure 6. Flowcytometry Profile of Anti-HER3 Full ECD Antibody in Breast Cancer Cell Lines. BT-474, JIMT-1 
and HCC-1954 cells were stained with adsorbed anti-HER3 Full ECD antibody as primary and FITC-labeled sheep 
anti-rabbit Ig as secondary antibody. Normal rabbit IgG at the same concentration was used as a negative control. The 
commercial PE-anti HER3 was also used as a positive control. 
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commercial HER3-ECD (Figure 5). No or negligible 
reactivity was observed with HER1 and HER4 proteins, 
but weak to moderate reactivity was noticed to HER2 
molecule. 
Binding of HER3-ECD specific polyclonal antibody to 
three different breast cancer cell lines 
We used flowcytometry assay to determine the binding 
of anti-HER3 full ECD to HER3 receptors on the surface 
of BT-474, JIMT-1 and HCC-1954 breast cancer cells 
lines. Because of high level of expression of HER2 on 
these cell lines, we used anti-HER2 Full ECD polyclonal 
antibody (Hosseini-Ghatar et al., 2017b) as a positive and 
non-immune rabbit IgG as a negative control. Although the 
flowcytometry results showed that all breast cancer cell 
lines were stained with anti-HER3 polyclonal antibody, the 
percentage of positive cells and MFI were less than those 
stained with anti-HER2 antibody (Figure 6). JIMT-1 and 
BT-474 had higher expression of HER3 on their surfaces 
and were then selected for the next experiments.  
Tumor growth inhibition by anti-HER3 subdomain 
antibodies
Anti-tumor effects of adsorbed polyclonal antibodies 
were assessed by XTT assay on growth of breast cancer 
cell lines. The results demonstrated that the anti-HER3 
subdomain polyclonal antibodies significantly inhibited 
the growth of BT-474 and JIMT-1 cell lines (Figure 7). 
Discussion
EGF receptor family is a major cell growth and 
differentiation regulator and any disturbance in this 
family may lead to a variety of cancers. Contrary to 
HER1 and HER2, which have been widely studied, 
HER3 was neglected for a long period of time due to 
possession of inactive kinase domain. Recent studies have 
demonstrated the role of HER3 in signalling and evaluated 
its importance in several clinical studies (Sergina and 
Moasser, 2007; Campbell et al., 2010; Kol et al., 2014). 
The presence of six phosphotyrosine residues in HER3 
carboxyl tail has pointed it as an intrinsic activator of 
PI3K-Akt pathway. PI3K-Akt signalling is associated 
to tumorgenesis and lack of control of this pathway has 
been reported in many types of cancer (Sithanandam 
and Anderson, 2008; Gala and Chandarlapaty, 2014). 
Although many therapeutic agents have been produced 
against tyrosine kinase receptors, in many cases, 
resistance to treatment has been reported. HER3, with 
its compensatory signalling potential in combination 
with TKI inhibitors, plays a critical role in PI3K/Akt 
activation and following the treatment failure (Sergina et 
al., 2007; Baselga and Swain, 2009). In addition, HER3 
is a preferred partner for HER2 which makes it the most 
active heterodimer in this family. Therefore, development 
of targeted therapeutics against HER3 is a promising tool 
for treatment of many HER3 overexpressing cancers (Ma 
et al., 2014). A large number of monoclonal antibodies 
(mAbs) have been generated against HER3 but non has 
so far received therapeutic approval (Jiang et al., 2012; 
Malm et al., 2016). Taking into consideration the fact 
that some epitopes located in different ECD subdomains 
of HER3 are biologically important because of their 
influence on ligand binding and receptor dimerization, 
therefore, targeting these epitopes is crucial for targeted 
therapy. Each mAb recognizes and attaches randomly to 
a specific epitope within a given subdomain and thereby 
affects the downstream signalling function of HER3. 
Some of these mAbs display inhibitory function and are 
considered as a potential therapeutic arsenal. Interestingly, 
the combination of some selected HER2 specific mAbs 
has shown synergistic inhibitory effects on tumor cells 
and are proposed for combination therapy. Approval of 
Pertuzumab by FDA as a combination therapy together 
with Trastuzumab in HER2 overexpressing metastatic 
breast cancer patients is an example of these mAbs 
(Scheuer et al., 2009; D’Souza et al., 2014; Yonesaka et 
al., 2016). We have recently produced a novel humanized 
mAb (Hersintuzumab) which displays superior tumor 
inhibitory activity in combination with Trastuzumab 
as compared to the combination of Pertuzumab and 
Trastuzumab (Amiri et al., 2018).The same principle may 
be applicable for HER3 specific mAbs. 
Based on these observations we decided to express 
Figure 7. Growth Inhibition of HER3 Positive Breast Cancer Cells by Anti-HER3 Polyclonal Antibody. BT-474 (a) 
and JIMT-1 (b) breast cancer cells were treated with different concentrations (5, 25 and 100 μg/ml) of anti-HER3 Full 
ECD, 100 μg/ml of anti-subdomain antibodies, 100 µg/ml of irrelevant non-immune rabbit IgG (negative control) and 
100 μg/ml of anti-HER2 Full ECD (positive control). The results represent mean and standard deviation of percent 
inhibition obtained by XTT assay for three independent experiments. (***) shows significant growth inhibition 
(p<0.001) of different treatments compared with negative control.
Samaneh Mansouri-Fard et al
Asian Pacific Journal of Cancer Prevention, Vol 21446
HER3 ECD subdomains as paired I+II and III+IV 
subdomains in a eukaryotic system and produce polyclonal 
antibodies trying to find out whether these antibodies can 
mimic the combination strategy and display differential 
inhibitory activity on HER3 expressing tumor cell lines. 
We did not construct single subdomains of HER3 ECD, 
because our previous experience with HER2 had shown 
that these isolated subdomains lacked some tertiary and 
quaternary structures leading to induction of polyclonal 
antibodies which either failed or weakly reacted with the 
native HER2 molecule (Hosseini-Ghatar et al., 2017a). 
We also encountered a similar problem with recombinant 
HER2 subdomain proteins expressed in prokaryotic 
system (Sadri-Ardalani et al., 2017). 
The paired subdomains of HER3 were fused to the 
mouse Fc γ2a gene to yield a fusion protein with higher 
immunogenicity, solubility and easy to purify using 
protein A or protein G column. Indeed, the presence of 
this tag enabled us to largely avoid aggregation of eluted 
proteins and collection of highly purified preparations with 
>95% purity, as judged by SDS-PAGE (Figure 1). These 
purified proteins were employed to produce polyclonal 
antibodies in rabbits. Serum titration of the immunized 
rabbits showed efficient immunization with both paired 
HER3 sub-domains and full HER3 ECD (Figure 2). The 
antibody preparations were adsorbed with IgG2a mAbs 
to remove anti-mouse Fc molecules. Adsorbed antibodies 
strongly reacted with the immunogens as well as the full 
HER3 ECD molecule, but failed to bind to mouse IgG2a 
(Figure 3). These results clearly indicated that our strategy 
worked fairly well and the purified polyclonal antibodies 
could be used to target HER3 positive tumor cells. The 
cross-reactivity experiment with other HER family 
members indicate lack of reactivity with HER1 and HER4 
and moderate to weak reactivity with HER2 (Figure 5). 
Of the three HER2 positive tumor cell lines tested with 
anti-HER3 full ECD antibody, two displayed moderate 
positive patterns (Figure 6), suggesting specific reactivity 
of the antibody at the specified concentration with only 
HER3, but not HER2 molecules. These two positive cell 
lines (BT-474 and JIMT-1) were selected for XTT assay 
to assess tumor inhibitory potential of the polyclonal 
antibodies. Interestingly, both HER3 full ECD and to a 
lesser extent HER3 paired subdomains induced 40-60% 
growth inhibition which was dose dependent (Figure 7). 
There seems to be no difference between I+II and III+IV 
subdomains specific polyclonal antibodies with regards to 
their inhibitory activity. Thus, both proteins are suitable 
for either passive or active targeted therapy of HER3 
positive cancer types, particularly breast cancer. This is 
very promising because tumor cells from 50-70% of these 
patients express HER3 which is higher than the frequency 
of HER2 overexpressing tumors in breast cancer patients 
(Ocana et al., 2012).
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